Table 2.
Demographic and baseline characteristicsa
| Characteristicb | Total study population (N = 272) |
| Age, years | |
| Mean ± SD | 62.9 ± 12.9 |
| Median (range) | 63.5 (22.0–97.0) |
| Females | 102 (37.5) |
| Race | |
| White | 200 (73.5) |
| Black | 58 (21.3) |
| Asian | 6 (2.2) |
| Other | 8 (2.9) |
| Medical history | |
| Hypertension | 246 (90.4) |
| Diabetes mellitus Type 1 | 10 (3.7) |
| Diabetes mellitus Type 2 | 110 (40.4) |
| Congestive heart failure | 47 (17.3) |
| Coronary artery disease | 94 (34.6) |
| Cerebral vascular accident | 24 (8.8) |
| Gastrointestinal disorders | 204 (75.0) |
| Duration of dialysis, years, mean ± SD | 3.7 ± 3.4 |
| Blood pressure, mean ± SD | |
| Systolic, mmHg | 140.4 ± 23.2 |
| Diastolic, mmHg | 73.4 ± 13.6 |
| Concomitant medication history | |
| Phosphate binders | |
| Calcium containing | |
| Calcium acetate | 62 (22.8) |
| Calcium carbonate | 38 (14.0) |
| Non-calcium containing | |
| Lanthanum | 47 (17.3) |
| Sevelamer | 131 (48.2) |
| Anti-hypertensives | |
| ACE inhibitors | 65 (23.9) |
| Angiotensin II receptor blockers | 47 (17.3) |
| Beta blockers | 131 (48.2) |
| Calcium channel blockers | 97 (35.7) |
| Diuretics | 66 (24.3) |
| Anti-adrenergic, central | 27 (9.9) |
| Anti-adrenergic, peripheral | 21 (7.7) |
| Erythropoiesis-stimulating agents | 196 (72.1) |
| Neuropsychiatric | 88 (32.4) |
a
ACE, angiotensin-converting enzyme.
b
Values shown are n (%) unless otherwise specified.